IGCAR / Ingenium Therap, Yale University - LARVOL DELTA

Ingenium, Yale University, and KAIST selected for 'KIAT International Joint R&D Project Research Project' [Google translation] (BioTimes) - "Ingenium Therapeutics...announced on the 10th that its research on 'CAR-NK using in vivo reprogramming', which it is jointly developing with Yale University and the Korea Advanced Institute of Science and Technology (KAIST), was recently selected as a finalist for the joint research project of the Global Industrial Technology Cooperation Center of the Korea Institute for Advancement of Technology (KIAT)...Ingenium will receive a total of KRW 6 billion in research funding from the Korea Institute for Advancement of Technology (KIAT) for three years at KRW 2 billion per year for joint research with Yale University and the Korea Advanced Institute of Science and Technology....The joint research between Ingenium, Yale University, and Korea Advanced Institute of Science and Technology (KAIST) is to develop a new candidate substance for 'in vivo CAR-NK treatment for intractable solid cancer'."

Financing • Oncology • Solid Tumor